Back to Newsroom

Clinical Data for BackBeat Medical’s Programmable Hypertension Control Therapy to Be Presented at ICI Meeting 2016

NEW HOPE, Pa., Nov. 29, 2016 /PRNewswire/ — BackBeat Medical Inc., a medical technology company developing novel cardiac stimulation-based therapies for hypertension and heart failure, today announced that clinical data for the company’s patented Programmable Hypertension Control (PHC) therapy will be presented at the Innovations in Cardiovascular Interventions (ICI) Meeting 2016, Dec. 4-6, in Tel Aviv, Israel.

The presentation will feature results from the first-in-man study of BackBeat’s PHC therapy including two years of follow-up data from patients who received BackBeat’s Moderato™ pacemaker incorporating the company’s proprietary pacing algorithms. Dr. Yuval Mika, CEO and co-founder, will deliver the presentation “Programmable Hypertension Control (PHC) – A Pacemaker-Mediated Novel Approach for the Treatment of Hypertension” during the session “Technology Parade I – Devices” at 9:50 a.m. IST on Monday, Dec. 5 in Room 4 at the David Intercontinental Convention Center.

Click here to read the full release